

Global Targeted Drug VEGF Inhibitors for NSCLC Market Growth (Status and Outlook) 2023-2029

<https://marketpublishers.com/r/G462FA1EF06EN.html>

Date: March 2023

Pages: 101

Price: US\$ 3,660.00 (Single User License)

ID: G462FA1EF06EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

LPI (LP Information)' newest research report, the “Targeted Drug VEGF Inhibitors for NSCLC Industry Forecast” looks at past sales and reviews total world Targeted Drug VEGF Inhibitors for NSCLC sales in 2022, providing a comprehensive analysis by region and market sector of projected Targeted Drug VEGF Inhibitors for NSCLC sales for 2023 through 2029. With Targeted Drug VEGF Inhibitors for NSCLC sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Targeted Drug VEGF Inhibitors for NSCLC industry.

This Insight Report provides a comprehensive analysis of the global Targeted Drug VEGF Inhibitors for NSCLC landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Drug VEGF Inhibitors for NSCLC portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Targeted Drug VEGF Inhibitors for NSCLC market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drug VEGF Inhibitors for NSCLC and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drug VEGF Inhibitors for NSCLC.

The global Targeted Drug VEGF Inhibitors for NSCLC market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Targeted Drug VEGF Inhibitors for NSCLC is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Targeted Drug VEGF Inhibitors for NSCLC is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Targeted Drug VEGF Inhibitors for NSCLC is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Targeted Drug VEGF Inhibitors for NSCLC players cover Roche, Pfizer, Allergan, Amgen, Biocon, Reliance Lifesciences, Beaconpharma, Celgene Corporation and Fujifilm Kyowa Kirin Biologics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drug VEGF Inhibitors for NSCLC market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Bevacizumab

Other

Segmentation by application

Squamous Cell Carcinoma of NSCLC

Adenocarcinoma of NSCLC

Large Cell Carcinoma of NSCLC

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Roche

Pfizer

Allergan

Amgen

Biocon

Reliance Lifesciences

Beaconpharma

Celgene Corporation

Fujifilm Kyowa Kirin Biologics

Hetero Drugs

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size 2018-2029
 - 2.1.2 Targeted Drug VEGF Inhibitors for NSCLC Market Size CAGR by Region 2018 VS 2022 VS 2029
- 2.2 Targeted Drug VEGF Inhibitors for NSCLC Segment by Type
 - 2.2.1 Bevacizumab
 - 2.2.2 Other
- 2.3 Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
 - 2.3.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size CAGR by Type (2018 VS 2022 VS 2029)
 - 2.3.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)
- 2.4 Targeted Drug VEGF Inhibitors for NSCLC Segment by Application
 - 2.4.1 Squamous Cell Carcinoma of NSCLC
 - 2.4.2 Adenocarcinoma of NSCLC
 - 2.4.3 Large Cell Carcinoma of NSCLC
- 2.5 Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application
 - 2.5.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size CAGR by Application (2018 VS 2022 VS 2029)
 - 2.5.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)

3 TARGETED DRUG VEGF INHIBITORS FOR NSCLC MARKET SIZE BY PLAYER

3.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Players

3.1.1 Global Targeted Drug VEGF Inhibitors for NSCLC Revenue by Players
(2018-2023)

3.1.2 Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by
Players (2018-2023)

3.2 Global Targeted Drug VEGF Inhibitors for NSCLC Key Players Head office and
Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 TARGETED DRUG VEGF INHIBITORS FOR NSCLC BY REGIONS

4.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size by Regions (2018-2023)

4.2 Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth
(2018-2023)

4.3 APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth (2018-2023)

4.4 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth (2018-2023)

4.5 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth
(2018-2023)

5 AMERICAS

5.1 Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country
(2018-2023)

5.2 Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
(2018-2023)

5.3 Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application
(2018-2023)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region

(2018-2023)

6.2 APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2018-2023)

6.3 APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application
(2018-2023)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Targeted Drug VEGF Inhibitors for NSCLC by Country (2018-2023)

7.2 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
(2018-2023)

7.3 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application
(2018-2023)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC by Region
(2018-2023)

8.2 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by
Type (2018-2023)

8.3 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by
Application (2018-2023)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 GLOBAL TARGETED DRUG VEGF INHIBITORS FOR NSCLC MARKET FORECAST

- 10.1 Global Targeted Drug VEGF Inhibitors for NSCLC Forecast by Regions (2024-2029)
 - 10.1.1 Global Targeted Drug VEGF Inhibitors for NSCLC Forecast by Regions (2024-2029)
 - 10.1.2 Americas Targeted Drug VEGF Inhibitors for NSCLC Forecast
 - 10.1.3 APAC Targeted Drug VEGF Inhibitors for NSCLC Forecast
 - 10.1.4 Europe Targeted Drug VEGF Inhibitors for NSCLC Forecast
 - 10.1.5 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Forecast
- 10.2 Americas Targeted Drug VEGF Inhibitors for NSCLC Forecast by Country (2024-2029)
 - 10.2.1 United States Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
 - 10.2.2 Canada Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
 - 10.2.3 Mexico Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
 - 10.2.4 Brazil Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
- 10.3 APAC Targeted Drug VEGF Inhibitors for NSCLC Forecast by Region (2024-2029)
 - 10.3.1 China Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
 - 10.3.2 Japan Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
 - 10.3.3 Korea Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
 - 10.3.4 Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
 - 10.3.5 India Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
 - 10.3.6 Australia Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
- 10.4 Europe Targeted Drug VEGF Inhibitors for NSCLC Forecast by Country (2024-2029)
 - 10.4.1 Germany Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
 - 10.4.2 France Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
 - 10.4.3 UK Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
 - 10.4.4 Italy Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
 - 10.4.5 Russia Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
- 10.5 Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Forecast by Region (2024-2029)
 - 10.5.1 Egypt Targeted Drug VEGF Inhibitors for NSCLC Market Forecast

- 10.5.2 South Africa Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
- 10.5.3 Israel Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
- 10.5.4 Turkey Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
- 10.5.5 GCC Countries Targeted Drug VEGF Inhibitors for NSCLC Market Forecast
- 10.6 Global Targeted Drug VEGF Inhibitors for NSCLC Forecast by Type (2024-2029)
- 10.7 Global Targeted Drug VEGF Inhibitors for NSCLC Forecast by Application (2024-2029)

11 KEY PLAYERS ANALYSIS

11.1 Roche

- 11.1.1 Roche Company Information
- 11.1.2 Roche Targeted Drug VEGF Inhibitors for NSCLC Product Offered
- 11.1.3 Roche Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
- 11.1.4 Roche Main Business Overview
- 11.1.5 Roche Latest Developments

11.2 Pfizer

- 11.2.1 Pfizer Company Information
- 11.2.2 Pfizer Targeted Drug VEGF Inhibitors for NSCLC Product Offered
- 11.2.3 Pfizer Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
- 11.2.4 Pfizer Main Business Overview
- 11.2.5 Pfizer Latest Developments

11.3 Allergan

- 11.3.1 Allergan Company Information
- 11.3.2 Allergan Targeted Drug VEGF Inhibitors for NSCLC Product Offered
- 11.3.3 Allergan Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
- 11.3.4 Allergan Main Business Overview
- 11.3.5 Allergan Latest Developments

11.4 Amgen

- 11.4.1 Amgen Company Information
- 11.4.2 Amgen Targeted Drug VEGF Inhibitors for NSCLC Product Offered
- 11.4.3 Amgen Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
- 11.4.4 Amgen Main Business Overview
- 11.4.5 Amgen Latest Developments

11.5 Biocon

- 11.5.1 Biocon Company Information
- 11.5.2 Biocon Targeted Drug VEGF Inhibitors for NSCLC Product Offered
- 11.5.3 Biocon Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
- 11.5.4 Biocon Main Business Overview
- 11.5.5 Biocon Latest Developments
- 11.6 Reliance Lifesciences
 - 11.6.1 Reliance Lifesciences Company Information
 - 11.6.2 Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Product Offered
 - 11.6.3 Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
 - 11.6.4 Reliance Lifesciences Main Business Overview
 - 11.6.5 Reliance Lifesciences Latest Developments
- 11.7 Beaconpharma
 - 11.7.1 Beaconpharma Company Information
 - 11.7.2 Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Product Offered
 - 11.7.3 Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
 - 11.7.4 Beaconpharma Main Business Overview
 - 11.7.5 Beaconpharma Latest Developments
- 11.8 Celgene Corporation
 - 11.8.1 Celgene Corporation Company Information
 - 11.8.2 Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Product Offered
 - 11.8.3 Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
 - 11.8.4 Celgene Corporation Main Business Overview
 - 11.8.5 Celgene Corporation Latest Developments
- 11.9 Fujifilm Kyowa Kirin Biologics
 - 11.9.1 Fujifilm Kyowa Kirin Biologics Company Information
 - 11.9.2 Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Product Offered
 - 11.9.3 Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
 - 11.9.4 Fujifilm Kyowa Kirin Biologics Main Business Overview
 - 11.9.5 Fujifilm Kyowa Kirin Biologics Latest Developments
- 11.10 Hetero Drugs
 - 11.10.1 Hetero Drugs Company Information

- 11.10.2 Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Product Offered
- 11.10.3 Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2018-2023)
- 11.10.4 Hetero Drugs Main Business Overview
- 11.10.5 Hetero Drugs Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Targeted Drug VEGF Inhibitors for NSCLC Market Size CAGR by Region (2018 VS 2022 VS 2029) & (\$ Millions)

Table 2. Major Players of Bevacizumab

Table 3. Major Players of Other

Table 4. Targeted Drug VEGF Inhibitors for NSCLC Market Size CAGR by Type (2018 VS 2022 VS 2029) & (\$ Millions)

Table 5. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2018-2023) & (\$ Millions)

Table 6. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)

Table 7. Targeted Drug VEGF Inhibitors for NSCLC Market Size CAGR by Application (2018 VS 2022 VS 2029) & (\$ Millions)

Table 8. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2018-2023) & (\$ Millions)

Table 9. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)

Table 10. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue by Players (2018-2023) & (\$ Millions)

Table 11. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Player (2018-2023)

Table 12. Targeted Drug VEGF Inhibitors for NSCLC Key Players Head office and Products Offered

Table 13. Targeted Drug VEGF Inhibitors for NSCLC Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

Table 14. New Products and Potential Entrants

Table 15. Mergers & Acquisitions, Expansion

Table 16. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Regions 2018-2023 & (\$ Millions)

Table 17. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Regions (2018-2023)

Table 18. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue by Country/Region (2018-2023) & (\$ millions)

Table 19. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Country/Region (2018-2023)

Table 20. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country

(2018-2023) & (\$ Millions)

Table 21. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Country (2018-2023)

Table 22. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2018-2023) & (\$ Millions)

Table 23. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)

Table 24. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2018-2023) & (\$ Millions)

Table 25. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)

Table 26. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2018-2023) & (\$ Millions)

Table 27. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Region (2018-2023)

Table 28. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2018-2023) & (\$ Millions)

Table 29. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)

Table 30. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2018-2023) & (\$ Millions)

Table 31. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)

Table 32. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Country (2018-2023) & (\$ Millions)

Table 33. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Country (2018-2023)

Table 34. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2018-2023) & (\$ Millions)

Table 35. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)

Table 36. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2018-2023) & (\$ Millions)

Table 37. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)

Table 38. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Region (2018-2023) & (\$ Millions)

Table 39. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Region (2018-2023)

Table 40. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2018-2023) & (\$ Millions)

Table 41. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)

Table 42. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2018-2023) & (\$ Millions)

Table 43. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)

Table 44. Key Market Drivers & Growth Opportunities of Targeted Drug VEGF Inhibitors for NSCLC

Table 45. Key Market Challenges & Risks of Targeted Drug VEGF Inhibitors for NSCLC

Table 46. Key Industry Trends of Targeted Drug VEGF Inhibitors for NSCLC

Table 47. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Regions (2024-2029) & (\$ Millions)

Table 48. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share Forecast by Regions (2024-2029)

Table 49. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Type (2024-2029) & (\$ Millions)

Table 50. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast by Application (2024-2029) & (\$ Millions)

Table 51. Roche Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors

Table 52. Roche Targeted Drug VEGF Inhibitors for NSCLC Product Offered

Table 53. Roche Targeted Drug VEGF Inhibitors for NSCLC Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 54. Roche Main Business

Table 55. Roche Latest Developments

Table 56. Pfizer Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors

Table 57. Pfizer Targeted Drug VEGF Inhibitors for NSCLC Product Offered

Table 58. Pfizer Main Business

Table 59. Pfizer Targeted Drug VEGF Inhibitors for NSCLC Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 60. Pfizer Latest Developments

Table 61. Allergan Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors

Table 62. Allergan Targeted Drug VEGF Inhibitors for NSCLC Product Offered

Table 63. Allergan Main Business

Table 64. Allergan Targeted Drug VEGF Inhibitors for NSCLC Revenue (\$ million),

Gross Margin and Market Share (2018-2023)

Table 65. Allergan Latest Developments

Table 66. Amgen Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors

Table 67. Amgen Targeted Drug VEGF Inhibitors for NSCLC Product Offered

Table 68. Amgen Main Business

Table 69. Amgen Targeted Drug VEGF Inhibitors for NSCLC Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 70. Amgen Latest Developments

Table 71. Biocon Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors

Table 72. Biocon Targeted Drug VEGF Inhibitors for NSCLC Product Offered

Table 73. Biocon Main Business

Table 74. Biocon Targeted Drug VEGF Inhibitors for NSCLC Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 75. Biocon Latest Developments

Table 76. Reliance Lifesciences Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors

Table 77. Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Product Offered

Table 78. Reliance Lifesciences Main Business

Table 79. Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 80. Reliance Lifesciences Latest Developments

Table 81. Beaconpharma Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors

Table 82. Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Product Offered

Table 83. Beaconpharma Main Business

Table 84. Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 85. Beaconpharma Latest Developments

Table 86. Celgene Corporation Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors

Table 87. Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Product Offered

Table 88. Celgene Corporation Main Business

Table 89. Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 90. Celgene Corporation Latest Developments

Table 91. Fujifilm Kyowa Kirin Biologics Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors

Table 92. Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Product Offered

Table 93. Fujifilm Kyowa Kirin Biologics Main Business

Table 94. Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 95. Fujifilm Kyowa Kirin Biologics Latest Developments

Table 96. Hetero Drugs Details, Company Type, Targeted Drug VEGF Inhibitors for NSCLC Area Served and Its Competitors

Table 97. Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Product Offered

Table 98. Hetero Drugs Main Business

Table 99. Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 100. Hetero Drugs Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Targeted Drug VEGF Inhibitors for NSCLC Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth Rate 2018-2029 (\$ Millions)

Figure 6. Targeted Drug VEGF Inhibitors for NSCLC Sales by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Figure 7. Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Country/Region (2022)

Figure 8. Targeted Drug VEGF Inhibitors for NSCLC Sales Market Share by Country/Region (2018, 2022 & 2029)

Figure 9. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type in 2022

Figure 10. Targeted Drug VEGF Inhibitors for NSCLC in Squamous Cell Carcinoma of NSCLC

Figure 11. Global Targeted Drug VEGF Inhibitors for NSCLC Market: Squamous Cell Carcinoma of NSCLC (2018-2023) & (\$ Millions)

Figure 12. Targeted Drug VEGF Inhibitors for NSCLC in Adenocarcinoma of NSCLC

Figure 13. Global Targeted Drug VEGF Inhibitors for NSCLC Market: Adenocarcinoma of NSCLC (2018-2023) & (\$ Millions)

Figure 14. Targeted Drug VEGF Inhibitors for NSCLC in Large Cell Carcinoma of NSCLC

Figure 15. Global Targeted Drug VEGF Inhibitors for NSCLC Market: Large Cell Carcinoma of NSCLC (2018-2023) & (\$ Millions)

Figure 16. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application in 2022

Figure 17. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Player in 2022

Figure 18. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Regions (2018-2023)

Figure 19. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size 2018-2023 (\$ Millions)

Figure 20. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size 2018-2023 (\$ Millions)

Figure 21. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size 2018-2023 (\$ Millions)

Figure 22. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size 2018-2023 (\$ Millions)

Figure 23. Americas Targeted Drug VEGF Inhibitors for NSCLC Value Market Share by Country in 2022

Figure 24. United States Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2018-2023 (\$ Millions)

Figure 25. Canada Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2018-2023 (\$ Millions)

Figure 26. Mexico Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2018-2023 (\$ Millions)

Figure 27. Brazil Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2018-2023 (\$ Millions)

Figure 28. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Region in 2022

Figure 29. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type in 2022

Figure 30. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application in 2022

Figure 31. China Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2018-2023 (\$ Millions)

Figure 32. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2018-2023 (\$ Millions)

Figure 33. Korea Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2018-2023 (\$ Millions)

Figure 34. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2018-2023 (\$ Millions)

Figure 35. India Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2018-2023 (\$ Millions)

Figure 36. Australia Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth 2018-2023 (\$ Millions)

Figure 37. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Country in 2022

Figure 38. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Type (2018-2023)

Figure 39. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share by Application (2018-2023)

Figure 40. Germany Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth

2018-2023 (\$ Millions)

Figure 41. France Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth

2018-2023 (\$ Millions)

Figure 42. UK Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth

2018-2023 (\$ Millions)

Figure 43. Italy Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth

2018-2023 (\$ Millions)

Figure 44. Russia Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth

2018-2023 (\$ Millions)

Figure 45. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size
Market Share by Region (2018-2023)

Figure 46. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size
Market Share by Type (2018-2023)

Figure 47. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size
Market Share by Application (2018-2023)

Figure 48. Egypt Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth
2018-2023 (\$ Millions)

Figure 49. South Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth
2018-2023 (\$ Millions)

Figure 50. Israel Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth
2018-2023 (\$ Millions)

Figure 51. Turkey Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth
2018-2023 (\$ Millions)

Figure 52. GCC Country Targeted Drug VEGF Inhibitors for NSCLC Market Size
Growth 2018-2023 (\$ Millions)

Figure 53. Americas Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029
(\$ Millions)

Figure 54. APAC Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$
Millions)

Figure 55. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$
Millions)

Figure 56. Middle East & Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size
2024-2029 (\$ Millions)

Figure 57. United States Targeted Drug VEGF Inhibitors for NSCLC Market Size
2024-2029 (\$ Millions)

Figure 58. Canada Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029
(\$ Millions)

Figure 59. Mexico Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$
Millions)

Figure 60. Brazil Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$ Millions)

Figure 61. China Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$ Millions)

Figure 62. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$ Millions)

Figure 63. Korea Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$ Millions)

Figure 64. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$ Millions)

Figure 65. India Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$ Millions)

Figure 66. Australia Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$ Millions)

Figure 67. Germany Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$ Millions)

Figure 68. France Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$ Millions)

Figure 69. UK Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$ Millions)

Figure 70. Italy Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$ Millions)

Figure 71. Russia Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$ Millions)

Figure 72. Spain Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$ Millions)

Figure 73. Egypt Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$ Millions)

Figure 74. South Africa Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$ Millions)

Figure 75. Israel Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$ Millions)

Figure 76. Turkey Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$ Millions)

Figure 77. GCC Countries Targeted Drug VEGF Inhibitors for NSCLC Market Size 2024-2029 (\$ Millions)

Figure 78. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share Forecast by Type (2024-2029)

Figure 79. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Market Share

Forecast by Application (2024-2029)

I would like to order

Product name: Global Targeted Drug VEGF Inhibitors for NSCLC Market Growth (Status and Outlook) 2023-2029

Product link: <https://marketpublishers.com/r/G462FA1EF06EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G462FA1EF06EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

